1251 related articles for article (PubMed ID: 23613383)
1. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
2. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz G; Schwedler K; Schmidt M; Barinoff J; Mundhenke C; Cufer T; Maartense E; de Jongh FE; Baumann KH; Bischoff J; Harbeck N; Lück HJ; Maass N; Zielinski C; Andersson M; Stein RC; Nekljudova V; Loibl S;
Eur J Cancer; 2011 Oct; 47(15):2273-81. PubMed ID: 21741829
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
6. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
7. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Valachis A; Nearchou A; Lind P; Mauri D
Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
[TBL] [Abstract][Full Text] [Related]
15. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
18. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
20. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
